Invention Grant
- Patent Title: X-ray psoralen activated cancer therapy (X-PACT)
-
Application No.: US17655683Application Date: 2022-03-21
-
Publication No.: US11992697B2Publication Date: 2024-05-28
- Inventor: Mark Oldham , Zakaryae Fathi , Wayne F. Beyer , Frederic A. Bourke, Jr. , Harold Walder , Mark Dewhirst , Neil L. Spector , Paul Yoon , Justus Adamson , David Alcorta , Kim Lyerly , Leihua Liu , Takuya Osada
- Applicant: IMMUNOLIGHT, LLC , DUKE UNIVERSITY
- Applicant Address: US MI Detroit
- Assignee: IMMUNOLIGHT, LLC,DUKE UNIVERSITY
- Current Assignee: IMMUNOLIGHT, LLC,DUKE UNIVERSITY
- Current Assignee Address: US MI Detroit
- Agency: TUCKER ELLIS, L.L.P.
- Agent J. Derek Mason
- The original application number of the division: US15434871 2017.02.16
- Main IPC: A61N5/06
- IPC: A61N5/06 ; A61K31/352 ; A61K41/00 ; A61N5/10

Abstract:
A method for treating a diseased site in a human or animal body is provided which includes injecting in a diseased site one or more phosphors which are capable of emitting ultraviolet or visible light into the body;
infusing the diseased site with a photoactivatable drug;
applying an initiation energy from an initiation energy source comprising an x-ray, gamma ray, or electron source to thereby initiate emission of ultraviolet or visible light into the body; and
controlling a dose of the initiation energy with a processor to produce (i) a cytotoxicity inside the diseased site of greater than 20% or (ii) a day-25 stable tumor volume,
wherein the processor is programmed to apply the initiation energy in a pulsed manner, wherein the initiation energy is delivered in either (i) a radiograph mode, or (ii) a pulsed fluoroscopy mode.
infusing the diseased site with a photoactivatable drug;
applying an initiation energy from an initiation energy source comprising an x-ray, gamma ray, or electron source to thereby initiate emission of ultraviolet or visible light into the body; and
controlling a dose of the initiation energy with a processor to produce (i) a cytotoxicity inside the diseased site of greater than 20% or (ii) a day-25 stable tumor volume,
wherein the processor is programmed to apply the initiation energy in a pulsed manner, wherein the initiation energy is delivered in either (i) a radiograph mode, or (ii) a pulsed fluoroscopy mode.
Public/Granted literature
- US20220226666A1 X-RAY PSORALEN ACTIVATED CANCER THERAPY (X-PACT) Public/Granted day:2022-07-21
Information query